2-triphenylmethylamino-4-carboxy-1,3-thiazole | 139355-13-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: 2-triphenylmethylamino-4-carboxy-1,3-thiazole
• 英文别名: 2-triphenylmethylamino-4-carboxy-1,3-thiazol；2-(tritylamino)-thiazole-4-carboxylic acid；2-(tritylamino)-1,3-thiazole-4-carboxylic acid
• CAS: 139355-13-8
• 化学式: C₂₃H₁₈N₂O₂S
• 分子量: 386.474
• InChiKey: CAUKNCDVPYXVHO-UHFFFAOYSA-N

物化性质

• 沸点：
  608.9±65.0 °C(Predicted)
• 密度：
  1.324±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  28
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.04
• 拓扑面积：
  90.5
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-triphenylmethylamino-4-carboxy-1,3-thiazole 在 三乙胺 、 N,N'-二环己基碳二亚胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 21.0h， 生成 ethyl 2-[2-[2-[2-(triphenylmethylamino)-1,3-thiazole-4-carboxamido]-1,3-thiazole-4-carboxamido]-1,3-thiazole-4-carboxamido]-1,3-thiazole-4-carboxylate
  参考文献：
  名称：

  Synthesis and evaluation of oligo-1,3-thiazolecarboxamide derivatives as HIV-1 reverse transcriptase inhibitors

  摘要：

  A set of oligo-1,3-thiazolecarboxamide derivatives able to interact with the minor groove of nucleic acids was synthesized. These oligopeptides contained different numbers of thiazole units presenting dimethylaminopropyl or EDTA moieties on the C-terminus, and aminohexanoyl or EDTA moieties on the N-terminus. The inhibition of such compounds on HIV-I reverse transcriptase activity was evaluated using different model template-primer duplexes: DNA DNA, RNA.DNA, DNA.RNA and RNA RNA. The biological properties of the thiazolecarboxamide derivatives were compared to those of distamycin, another minor groove binder which contains three pyrrole rings. Similar to distamycin, the thiazole containing oligopeptides were good inhibitors of the reverse transcription reaction in the presence of DNA.DNA. But in contrast to distamycin, the oligothiazolide derivatives were able to inhibit reverse transcription in the presence of RNA.DNA or DNA RNA template-primers. Both distamycin and oligothiazolecarboxamides had low affinity for RNA RNA duplexes. The inhibition obtained with the newly synthesized thiazolecarboxamides showed that these compounds were more powerful and versatile inhibitors of the RT-dependent polymerization than the natural minor groove binder distamycin. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(00)00029-8
• 作为产物：
  描述：

  ethyl 2-tritylaminothiazole-4-carboxylate 在 吡啶 、 sodium hydroxide 、 乙醇 、 水 、 溶剂黄146 作用下， 以 吡啶 、 乙醇 、 水 为溶剂， 以72%的产率得到2-triphenylmethylamino-4-carboxy-1,3-thiazole
  参考文献：
  名称：

  Modulators of the glucocorticoid receptor, AP-1, and/or NF-kB activity and use thereof

  摘要：

  提供了一类新型的非甾体化合物，用于治疗与糖皮质激素受体、AP-1和/或NF-κB活性调节相关的疾病，包括肥胖、糖尿病、炎症和免疫性疾病，其结构如下式（I）：其中X为S、O或N；Z为—T—COOR1或—T—COR1；T、R、R1、Ra、Rb、Rc、Rd、Z、A和B在此处有定义。还提供了包含上述化合物的药物组合物和治疗肥胖、糖尿病以及炎症或免疫相关疾病的方法。

  公开号：

  US20060154975A1

文献信息

• Modulators of the glucocorticoid receptor, AP-1, and/or NF-kB activity and use thereof
  申请人：Yang V. Bingwei

  公开号：US20060154975A1

  公开（公告）日：2006-07-13

  A class of novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula (I): where X is S, O or N; Z is —T—COOR 1 or —T—COR 1 ; and T, R, R 1 , R a , R b , R c , R d , Z, A and B are defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising said compounds.

  提供了一类新型的非甾体化合物，用于治疗与糖皮质激素受体、AP-1和/或NF-κB活性调节相关的疾病，包括肥胖、糖尿病、炎症和免疫性疾病，其结构如下式（I）：其中X为S、O或N；Z为—T—COOR1或—T—COR1；T、R、R1、Ra、Rb、Rc、Rd、Z、A和B在此处有定义。还提供了包含上述化合物的药物组合物和治疗肥胖、糖尿病以及炎症或免疫相关疾病的方法。
• Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
  申请人：Bristol-Myers Squibb Company

  公开号：US07411071B2

  公开（公告）日：2008-08-12

  A class of novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula (I): where X is S, O or N; Z is —T—COOR1 or —T—COR1; and T, R, R1, Ra, Rb, Rc, Rd, Z, A and B are defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising said compounds.

  提供了一类新型非类固醇化合物，其在治疗与糖皮质激素受体、AP-1和/或NF-κB活性调节相关的疾病方面具有用途，包括肥胖症、糖尿病、炎症和免疫性疾病，其结构式为（I）：其中X为S、O或N；Z为—T—COOR1或—T—COR1；T、R、R1、Ra、Rb、Rc、Rd、Z、A和B在此定义。还提供了包含该化合物的药物组合物和治疗肥胖症、糖尿病及炎症或免疫相关疾病的方法。
• MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF
  申请人：Bristol-Myers Squibb Company

  公开号：EP1844028A1

  公开（公告）日：2007-10-17
• US7411071B2
  申请人：——

  公开号：US7411071B2

  公开（公告）日：2008-08-12
• [EN] MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-?B ACTIVITY AND USE THEREOF<br/>[FR] MODULATEURS DE RECEPTEUR GLUCOCORTICOIDE, D'AP-1, ET/OU D'ACTIVITE NF$G(K)B, ET UTILISATION CORRESPONDANTE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2006076633A1

  公开（公告）日：2006-07-20

  [EN] A class of novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-?B activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula (I), where X is S, O or N; Z is -T-COOR¹ or çT-COR¹;and T, R, R¹ R^a, R^b, R^c, R^d, Z, A and B are defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising said compounds.
  [FR] L'invention concerne une classe de composés non stéroïdes utiles dans le traitement de maladies associées à la modulation du récepteur glucocorticoïde, de l'AP-1 et/ou de l'activité NF-?B, y compris l'obésité, le diabète, les maladies inflammatoires et immunes connexes, de structure (I), sachant que X est S, O ou N; que Z est -T-COOR¹ ou T-COR¹; et que T, R, R¹ R^a, R^b, R^c, R^d, Z, A et B sont tels que définis dans la description. On décrit aussi des compositions pharmaceutiques et des procédés de traitement des maladies susmentionnées faisant appel aux composés en question.